Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020

January 2020 | 107 pages | ID: RD14F5F7AA8EN
Global Markets Direct

Abstracts

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 7, 7, 3 and 4 respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Ahn-Gook Pharmaceutical Co Ltd
CalyGene Biotechnology Inc
Cancer Advances Inc
Changchun Serene Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cinclus Pharma AG
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Renexxion LLC
Sam-A Pharm Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Trio Medicines Ltd
XuanZhu Pharma Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc